RE:RE:RE:genacol procuctsgettothechopper wrote: TripleEm wrote: gettothechopper wrote: so know rather than focusing on being a bio-pharma companies attempting to gain DIN's they put a label on a mock-up of a supplement product? I've been to supplement conferences before and it's as easy as ordering the product and slapping another label and the same product that may or may not work? where are they getting the cannabis for this anyway? btw. genacol products don't have a level of success. they'll sell it amazon, to people once....and then they'll say that it doesn't work for them. great!
Looks like laminated plastic tubing to me, no sticker here.
AND here is where the mj is supplied from,
Tetra and Aphria will enter into a joint supply agreement, with Aphria supplying dried medical cannabis under its ACMPR license, and Tetra packaging the product using the manufacturing process developed for its in-progress clinical drug trial for PPP001. The formulation and packaging will be completed by Tetra, under its CDSA dealer’s licence Read more at https://www.stockhouse.com/news/press-releases/2017/04/19/tetra-bio-pharma-aphria-announce-plans-for-the-joint-distribution-of-dried#jBPhd06di3lyufVB.99 JMO, GLTA...
GO TETRA GO>>>
have you any idea what a mockup is?
Thought ppp001 was the walkable stuff.this doesn't look smokable?
Yup it's a double,replica,copy, what ever. Then i was saying that ther is no sticker put on it , it is a fabricated piece, it is defenatly not smokeable because it is a gel, Says right on the tube. Less you want to try it, haha.
Tetra Bio-Pharma will develop a cannabinoid derived oral capsule and a topical cream for treating joint pain and inflammation. Read more at https://www.stockhouse.com/news/press-releases/2018/08/14/genacol-canada-corporation-and-tetra-bio-pharma-team-up-to-bring-innovative#peLCxmiB37pwvuDP.99 OTTAWA, ONTARIO--(Marketwired - May 23, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a definitive agreement with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion. The recent press release on May 17th for the filing of a patent in ocular disease combined with the patents from Panag in the ocular space make this agreement very lucrative.
Per the definitive agreement, Tetra will have exclusive access to sell the ocular and topical drug products in North America with right of first negotiation for outside U.S. and Canadian territories. In addition, Tetra will have a right of first negotiation for future cannabinoid-based products.
Read more at https://www.stockhouse.com/news/press-releases/2017/05/23/tetra-bio-pharma-signs-definitive-agreement-for-two-products-with-panag-pharma#OfM2Myk2F5JWc7fW.99 Now get to your chopper...
JMO, GLTA...
GO TETRA GO>>>